Your browser doesn't support javascript.
loading
Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma.
Liu, Zhuohao; Zhou, Jiayi; Yang, Xinzhi; Liu, Yuchen; Zou, Chang; Lv, Wen; Chen, Cheng; Cheng, Kenneth King-Yip; Chen, Tao; Chang, Lung-Ji; Wu, Dinglan; Mao, Jie.
Afiliación
  • Liu Z; Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
  • Zhou J; Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
  • Yang X; The Third School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China.
  • Liu Y; Department of Neurosurgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
  • Zou C; Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
  • Lv W; The Third School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China.
  • Chen C; Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
  • Cheng KK; The Third School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China.
  • Chen T; Department of Neurosurgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
  • Chang LJ; Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China.
  • Wu D; School of Medicine, Life and Health Sciences, The Chinese University of Hong Kong (Shenzhen), Shenzhen, Guangdong, China.
  • Mao J; Department of Neurosurgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Mol Cancer ; 22(1): 3, 2023 01 09.
Article en En | MEDLINE | ID: mdl-36617554
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Glioblastoma / Receptores Quiméricos de Antígenos Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Mol Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Glioblastoma / Receptores Quiméricos de Antígenos Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Mol Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China